Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision tag on the page updated from v3.5.3 to v3.5.4, signaling a new deployment of the page. This update does not change the trial details or related information.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThis update changes the ClinicalTrials.gov page’s displayed revision/version from v3.5.0 to v3.5.3, indicating an internal platform release without altering the study information presented.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision label updated to v3.5.0; the previous v3.4.3 label was removed.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check111 days agoChange DetectedThe visible change is a minor revision label updated from v3.4.1 to v3.4.2; no alterations to the study content, eligibility criteria, or essential page functionality are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check118 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.